ReviewHepatology international2017
A brief review on prognostic models of primary biliary cholangitis.
Review in Hepatology international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Autoantibodies in the diagnostics, prognostics and follow-up of primary biliary cholangitis.Journal of translational autoimmunity · 2026Review
- Direct bilirubin was superior to total bilirubin in predicting the long-term outcomes of patients with primary biliary cholangitis.BMC gastroenterology · 2026Article
- [Research progress on the diagnostic performance and predictive accuracy of different prognostic scores as non-invasive liver fibrosis models for primary biliary cholangitis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- [Response to Primary Biliary Cholangitis Treatment: Influencing Factors and the Role in Prognosis Prediction].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2023Article
- Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021).Journal of clinical and translational hepatology · 2023Article
- APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.Hepatology international · 2022Article
- [Guidelines on the diagnosis and management of primary biliary cholangitis (2021)].Zhonghua nei ke za zhi · 2021Article
- An Examination of the Evidence Behind Biochemical Markers in Primary Biliary Cholangitis.Gastroenterology & hepatology · 2021Article
- Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis.Journal of clinical and translational hepatology · 2021Article
- Evaluation of the United Kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population.JGH open : an open access journal of gastroenterology and hepatology · 2020Article
- Erythrocyte count is associated with prognosis in Chinese patients with primary biliary cholangitis.Experimental and therapeutic medicine · 2020Article
- Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2018Article
- Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea.Clinical and molecular hepatology · 2018Review
- [Research advances in primary biliary cholangitis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune liver disease characterized by progressive destruction of small intrahepatic bile ducts. If left untreated, PBC may eventually result in end-stage liver disease. For better management of PBC and optimal allocation of medical resources, it is pivotal to accurately estimate the prognosis of patients with PBC. This article will briefly review the models that predict long-term outcome of PBC patients, with special focus on the applicability, strengths and limitations of the widely used models reported from 1983 to 2016. Among many, the Mayo score has been extensively validated and considered as the classic prognostic model for untreated PBC patients, whereas the well-validated Paris I and Paris II criteria are mainly used in ursodeoxycholic acid (UDCA)-treated patients with advanced PBC (stage III-IV) and early PBC (stege I-II), respectively. Based on multicenter studies with large sample sizes, the recently reported GLOBE score and UK-PBC score seem to be superior to previous models and can be applied in patients with different stages of PBC who are already on UDCA therapy, but further external validation may be justified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.